Not so puzzling: Actavis, Forest pieces fit strategic gaps
This article was originally published in Scrip
The $25bn merger of brand-name drug marketer Forest Laboratories into generics maker Actavis isn't so puzzling, considering Actavis's increased focus on specialty medicines and the pent-up demand for significant returns for Forest shareholders.
You may also be interested in...
Brent Saunder’s Vesper Healthcare Acquisition Corp. wants to raise up to $460m in a forthcoming IPO to buy companies in health care and medical market niches including wellness.
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.